<h3>Introduction</h3> 85% of children with uncontrolled, moderate-to-severe asthma have type 2 inflammatory asthma (baseline blood eosinophils ≥150 cells/µL or FeNO ≥20 ppb); many exhibit an allergic phenotype. Asthma can lead to severe and/or frequent exacerbations and abnormal lung function. Dupilumab, a fully human monoclonal antibody, blocks signaling of IL-4/-13, key drivers of type 2 inflammation. In phase 3 VOYAGE (NCT02948959), add-on dupilumab vs placebo reduced severe exacerbations, and improved lung function and asthma control in children aged 6–11 years with uncontrolled, moderate to severe type 2 asthma. Dupilumab demonstrated an acceptable safety profile. This analysis compared the effect of dupilumab vs placebo on lung function in VOYAGE patients with type 2 asthma stratified by allergen sensitization status. <h3>Methods</h3> Children were classified as non-sensitized (n=75; no perennial aeroallergen-specific IgE ≥0.35 kU/L at baseline), monoallergen- (n=58) or multiallergen (n=203)-sensitized (1 [mono-] or >1 [multi-] aeroallergen-specific IgE ≥0.35 kU/L, respectively). Least squares mean (LSM) change from baseline in pre-bronchodilator percent predicted forced expiratory volume in 1 second (pre-BD ppFEV<sub>1</sub>) was assessed. <h3>Results</h3> Dupilumab vs placebo significantly improved pre-BD ppFEV<sub>1</sub> in multiallergen-sensitized patients at Weeks 2 (LSM difference [95% CI]: 5.3 percentage points [1.4–9.2]; P<0.01) and 52 (9.0 percentage points [4.0–14.1]; P<0.001) and in monoallergen-sensitized patients at Week 52 (10.1 percentage points [4.2–16.1]; P<0.01). <h3>Conclusion</h3> Dupilumab improved pre-BD ppFEV<sub>1</sub> as early as Week 2 in children with moderate-to-severe type 2 asthma and mono- or multi-allergen sensitizations; improvements were sustained through Week 52. Small sample sizes limited efficacy comparisons among the 3 groups.